Anti-Human CD3 [Clone OKT-3] — Purified in vivo PLATINUM™ Functional Grade

The OKT3 antibody clone has several important in vivo applications in mice, primarily focused on studying human immune responses and preventing complications in xenograft models.

Prevention of Xenogeneic Graft-Versus-Host Disease

One of the most significant applications of OKT3 in mice is preventing xenogeneic graft-versus-host disease (GVHD) in humanized mouse models. When human hematopoietic cells are transplanted into immunodeficient mice, coinjected human T cells can rapidly expand and cause GVHD. OKT3 treatment effectively addresses this challenge through two approaches: intraperitoneal injection within 48 hours of transplantation, or short-term in vitro incubation of cells with the antibody immediately before transplant. Importantly, unlike antithymocyte globulin (ATG) which causes dramatic loss of SCID-repopulating cells, OKT3 treatment abrogates GVHD risk while preserving engraftment potential.

Human T Cell Elimination in Xenograft Studies

OKT3 demonstrates potent activity in eliminating human T cells from humanized mice. When administered at 10 mg/kg to humanized mice with significant T cell populations in peripheral blood, OKT3 causes nearly complete elimination of CD45+CD3+ cells. This targeted specificity is particularly valuable because it removes problematic T cells while preserving other human cell populations, as evidenced by readily detectable human CD3-negative cells in treated mice.

Streamlining Xenograft Research

OKT3 treatment has revolutionized xenograft protocols by enabling the use of unfractionated cord blood instead of requiring highly purified CD34+ cells. This eliminates the need for expensive and time-consuming cell purification procedures. OKT3-treated unfractionated cord blood produces robust, durable hematopoietic xenografts in both primary and secondary mice that are indistinguishable from grafts obtained using purified CD34+ cells. This approach significantly reduces both the cost and time required for xenograft studies while maintaining experimental quality.

Rescue of Contaminated Leukemia Samples

OKT3 proves particularly valuable for rescuing patient leukemia samples that contain substantial human T cell contamination, which would otherwise cause GVHD and compromise the xenograft. This application is crucial for translational research using primary patient samples.

OKT-3, a monoclonal antibody targeting the CD3 receptor on T cells, is commonly used in immunosuppressive regimens and research related to T-cell activation and immunomodulation. Here are some other antibodies and proteins frequently studied alongside OKT-3:

1. Antithymocyte Globulins (ATG) and Antilymphocyte Globulins (ALG): These are polyclonal antibodies used alongside OKT-3 for immunosuppression in organ transplantation. They target various surface molecules on T and B cells, including CD3, and are effective in preventing graft rejection.

2. Anti-CD4 and Anti-CD8 Antibodies: While not typically used in combination with OKT-3 for clinical purposes, these antibodies are used in research to study T-cell subsets and their roles in immune responses. In some contexts, they can be used to further modulate T-cell activity.

3. Interleukins (e.g., IL-1, IL-2): These cytokines play crucial roles in T-cell activation and proliferation. IL-2, in particular, is often studying in conjunction with OKT-3 to understand T-cell activation mechanisms.

4. CS1-OKT3 Dual Specific Bivalent Antibody: This engineered antibody combines specificity for the CD3 receptor with another antigen (CS1), used to enhance T-cell cytotoxic activity against specific targets, such as CS1-bearing multiple myeloma tumors.

In summary, OKT-3 is often used in conjunction with other immunosuppressive agents or in research with various cytokines and antibodies to modulate immune responses.

The key findings from scientific literature about clone OKT-3 (OKT3), a murine monoclonal antibody targeting CD3 on human T cells, include:

• Immunosuppression and Clinical Use: OKT3 induces profound immunosuppression by binding to the CD3 complex on T cells, effectively eliminating circulating T cells and inhibiting their function. It is widely used to treat acute organ transplant rejection, especially when other immunosuppressive agents fail.

• Infection Risk in Patients: Clinical studies indicate an increased incidence and severity of infections—especially bacterial and nonbacterial (fungal/viral)—in transplant patients treated with OKT3 compared to those on conventional immunosuppression, most notably in those already critically ill. A trend toward a higher risk of life-threatening infections is particularly evident in populations receiving OKT3 as rescue therapy.

• Mechanism of Action: OKT3 monoclonal antibody inhibits cytotoxic T cell-mediated lysis and allogeneic immune responses, primarily by binding to the T-cell antigen recognition complex (CD3). This binding not only blocks activation but also, at lower concentrations, has a mitogenic effect—stimulating T-cell proliferation in certain contexts. The antibody’s immunosuppressive effect is unique among T-cell-reactive monoclonals.

• Novel Findings—Exosomes: Exosomes (nanovesicles) released by OKT3-producing hybridomas bear functional, membrane-anchored OKT3 antibodies and can potently induce cytokine release from both CD4+ and CD8+ T cells. Notably, these exosomal antibodies are more effective in stimulating T-cell cytokine production than the soluble (conventional) OKT3 antibody. This suggests exosome-based delivery could enhance the efficacy and tissue targeting of antibody therapies.

• Oral Administration (Experimental): Orally administered OKT3, though not a clinical standard, was shown in one study to be biologically active—modulating human T cell proliferation, suppressing pro-inflammatory (Th1/Th17) responses, and increasing regulatory cytokines (e.g., TGF-β, IL-10). This demonstrates an immunomodulatory effect even without the risks of intravenous antibody therapy, although this is experimental.

• Immunophenotyping and Defect Illustration: OKT3 is a standard tool in immunology for marking and functionally characterizing T cells. CD3 (targeted by OKT3) is a key marker of immune response efficiency, and defects in this component can result in immunodeficiency.

• Differentiation from Other Monoclonals: Among T-cell monoclonals, OKT3 distinguishes itself through its universal reactivity with all T cells and unique functional properties (both activation and suppression).

In summary, clone OKT-3 (OKT3) is foundational in immunology, both as a therapeutic for acute transplant rejection and as a basic research tool to define T cell function and activation. Key concerns relate to the heightened infection risk due to profound immunosuppression and the emerging potential of exosome-associated delivery to improve antibody therapeutics.

OKT-3 (anti-CD3) dosing regimens in mouse models show considerable variation depending on the type of mouse (e.g., conventional, humanized, autoimmune-prone) and experimental purpose (e.g., immune activation vs. immune modulation).

• In humanized mouse models:

  • A single intravenous dose of 1 mg OKT3 per mouse is commonly used to study T cell activation and cytokine release.
  • Another study used 20 μg OKT3 per 10 g body weight, typically administered as a single intravenous injection and then monitoring immune response over hours to days.
  • Dose-dependent induction of cytokines, including IFN-γ, TNF-α, IL-10, and others, is consistently observed after administration.
  • Timepoints for sampling (e.g., 1h, 2h, 6h, 24h, 48h, and 96h after treatment) and endpoints for analysis also vary by study.

• Model variation matters:

  • PBMC-humanized mice and CBC-humanized mice (derived from cord blood) respond differently: PBMC models often feature predominantly T and B cells and appear to tolerate higher levels of activation and cytokine release, whereas CBC models include more myeloid and NK cell populations influencing cytokine patterns and immune cell depletion.
  • In PBMC-humanized mice, higher and transient cytokine surges (e.g., TNF-α, IFN-γ) are detected shortly after OKT3 dosing, with distinctive depletion and activation kinetics compared to cord blood models.

• Autoimmune models:

  • For inducing regulatory T cells, especially in diabetes research, lower doses and repeated low-dose regimens (e.g., separated by days) are favored.
  • In NOD (non-obese diabetic) mice, titrated regimens are used to maximize immune tolerance without triggering robust activation/cytokine storm.

• Oral administration:

  • Although not typical for most immunological assays in mice, oral OKT3 has been explored at doses ranging from 0.2 to 5 mg daily (with effects more consistently seen at 1 mg daily) to induce immune regulation rather than activation.

Summary Table: OKT-3 Dosing Approaches by Mouse Model

Key points:

• Dose, route, and schedule are tailored to experimental aims (e.g., immune activation, tolerance induction, depletion).
• Cytokine profiles and immune cell changes depend not only on dose, but also mouse model immune landscape and baseline activation.
• Inter-study variation is substantial; always consult the specific protocol of the referenced study.

If you need dosing specifics for a particular mouse strain or disease model, please clarify for a targeted summary.